플러스100%마이너스

통합검색
닫기

KMCRIC 챗봇에게

질문하기!

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Effectiveness of Curcuma longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis : A Randomized Trial.

Authors

Wang Z, Jones G, Winzenberg T, Cai G, Laslett LL, Aitken D, Hopper I, Singh A, Jones R, Fripp J, Ding C, Antony B.

Journal

Ann Intern Med.

Year

2020

Vol (Issue)

173(11)

Page

861-869.

doi

10.7326/M20-0990.

PMID

32926799

Url

http://www.ncbi.nlm.nih.gov/pubmed/32926799

MeSH

Arthralgia / drug therapy
Arthralgia / etiology
Curcuma
Double-Blind Method
Female
Humans
Knee Joint / diagnostic imaging
Knee Joint / drug effects
Magnetic Resonance Imaging
Male
Middle Aged
Osteoarthritis, Knee / complications
Osteoarthritis, Knee / diagnostic imaging
Osteoarthritis, Knee / drug therapy*
Pain Measurement
Phytotherapy* / methods
Plant Extracts / therapeutic use*
Synovitis / drug therapy*
Synovitis / etiology
Ultrasonography

Keywords

한글 키워드

KMCRIC
Summary & Commentary

KMCRIC 비평 보기 +

Korean Study

Abstract

Background: Current pharmacologic therapies for patients with osteoarthritis are suboptimal.

Objective: To determine the efficacy of Curcuma longa extract (CL) for reducing knee symptoms and effusion-synovitis in patients with symptomatic knee osteoarthritis and knee effusion-synovitis.

Design: Randomized, double-blind, placebo-controlled trial. (Australian New Zealand Clinical Trials Registry: ACTRN12618000080224).

Setting: Single-center study with patients from southern Tasmania, Australia.

Participants: 70 participants with symptomatic knee osteoarthritis and ultrasonography-defined effusion-synovitis.

Intervention: 2 capsules of CL (n = 36) or matched placebo (n = 34) per day for 12 weeks.

Measurements: The 2 primary outcomes were changes in knee pain on a visual analogue scale (VAS) and effusion-synovitis volume on magnetic resonance imaging (MRI). The key secondary outcomes were change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and cartilage composition values. Outcomes were assessed over 12 weeks.

Results: CL improved VAS pain compared with placebo by -9.1 mm (95% CI, -17.8 to -0.4 mm [P = 0.039]) but did not change effusion-synovitis volume (3.2 mL [CI, -0.3 to 6.8 mL]). CL also improved WOMAC knee pain (-47.2 mm [CI, -81.2 to -13.2 mm]; P = 0.006) but not lateral femoral cartilage T2 relaxation time (-0.4 ms [CI, -1.1 to 0.3 ms]). The incidence of adverse events was similar in the CL (n = 14 [39%]) and placebo (n = 18 [53%]) groups (P = 0.16); 2 events in the CL group and 5 in the placebo group may have been treatment related.

Limitation: Modest sample size and short duration.

Conclusion: CL was more effective than placebo for knee pain but did not affect knee effusion-synovitis or cartilage composition. Multicenter trials with larger sample sizes are needed to assess the clinical significance of these findings.

Primary funding source: University of Tasmania and Natural Remedies Private Limited.

국문초록

Language

영어

첨부파일